ExicureXCUR
XCUR
About: Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Employees: 6
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
583% more capital invested
Capital invested by funds: $156K [Q2] → $1.06M (+$907K) [Q3]
0.86% less ownership
Funds ownership: 5.64% [Q2] → 4.78% (-0.86%) [Q3]
33% less funds holding
Funds holding: 15 [Q2] → 10 (-5) [Q3]
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for XCUR.
Financial journalist opinion
Neutral
Business Wire
20 hours ago
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.
Neutral
Business Wire
1 month ago
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results.
Neutral
Business Wire
3 months ago
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company's listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 2024. The Company is diligently working to timely satisfy the terms of the Panel's requests and to ensure.
Neutral
Business Wire
3 months ago
Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation.
Neutral
Business Wire
3 months ago
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28, 2024 under the new CUSIP number 30205M 309. Exicure's common stock.
Neutral
Business Wire
4 months ago
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting.
Neutral
Business Wire
4 months ago
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting.
Neutral
Business Wire
4 months ago
Exicure, Inc. Reports Second Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2024 Financial Results.
Neutral
Business Wire
4 months ago
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics.
Neutral
Business Wire
4 months ago
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Receives Positive Listing Determination from Nasdaq.
Charts implemented using Lightweight Charts™